Centene price target lowered to $90 from $93 at Barclays

Barclays analyst Steve Valiquette lowered the firm’s price target on Centene to $90 from $93 and keeps an Overweight rating on the shares. The analyst expects five of the seven managed care companies under the firm’s coverage to beat Q1 earnings estimates on better medical loss ratio.